Patent · US Active

Anti-AREG/HB-EGF antibodies and treatment

US8846868B2 · kind B2 · utility

0Cited by

11References

11Claims

0Family size

Assignee

Fusion Antibodies Limited · IE

Inventors

Jill Caswell · Belfast, GB
Shane Olwill · Freising, DE
James A. Johnston · Windham, US
Richard Buick · Belfast, GB
Thomas Jaquin · Belfast, GB
Declan Doherty · Belfast, GB
Christopher Scott · Foxford, IE

Key dates

Filing date	Apr 17, 2009
Grant date	Sep 30, 2014
Priority date	—
Expiry date	Feb 24, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/74
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.